^
    Back
    Association details:
    Biomarker:LINC02751 rs1872285
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2023
    Title:

    Genomic Variants Associated with Response to Immune Checkpoint Inhibitors Amongst Asian Patients with Advanced NSCLC

    Published date:
    08/08/2023
    Excerpt:
    The GWAS uncovered 7 novel genetic biomarkers with suggestive evidence of association with ICI response: BMP6 rs267807 (P = 1.80E-06, OR (95%CI) = 30.75 (3.18-297.51)); IGFBP7-AS1rs6828212 (P = 9.36E-07,OR (95%CI) = 33.46 (3.23-347.08)), IGFBP7-AS1 rs4516785 (P = 1.14E-06, OR (95%CI) = 24.07 (2.96-195.70)), IGFBP7-AS1 rs10033422 (P = 1.34E-06, OR (95%CI) = 32.96 ( 3.16-343.61)); LINC02468 rs10841449 (P = 1.51E-06, OR (95%CI) = 0.11 ( 0.04-0.33)); LINC02751 rs1872285 (P = 3.34E-06, OR (95%CI) = 0.14 (0.05-0.38)) and LDLRAD4 rs16940509 (P = 4.25E-06, OR (95%CI) = 0.16 (0.06-0.39)....This GWAS pharmacogenomic study identified 7 novel variants in 4 genes associated with ICI response in advanced NSCLC.